Eric L Sievers
Overview
Explore the profile of Eric L Sievers including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
35
Citations
3586
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Sekeres M, Lancet J, Wood B, Grove L, Sandalic L, Sievers E, et al.
Haematologica
. 2012 Jul;
98(1):119-28.
PMID: 22801961
Improving outcomes in older adults with acute myeloid leukemia remains a formidable challenge. Lintuzumab (SGN-33; HuM195) is a humanized monoclonal antibody directed against CD33, which is expressed on the majority...
12.
Senter P, Sievers E
Nat Biotechnol
. 2012 Jul;
30(7):631-7.
PMID: 22781692
Progress has been made recently in developing antibody-drug conjugates (ADCs) that can selectively deliver cancer drugs to tumor cells. In principle, the idea is simple: by attaching drugs to tumor-seeking...
13.
Pro B, Advani R, Brice P, Bartlett N, Rosenblatt J, Illidge T, et al.
J Clin Oncol
. 2012 May;
30(18):2190-6.
PMID: 22614995
Purpose: Systemic anaplastic large-cell lymphoma (ALCL) is an aggressive subtype of T-cell lymphoma characterized by the uniform expression of CD30. The antibody-drug conjugate brentuximab vedotin delivers the potent antimicrotubule agent...
14.
Younes A, Gopal A, Smith S, Ansell S, Rosenblatt J, Savage K, et al.
J Clin Oncol
. 2012 Mar;
30(18):2183-9.
PMID: 22454421
Purpose: Brentuximab vedotin is an antibody-drug conjugate (ADC) that selectively delivers monomethyl auristatin E, an antimicrotubule agent, into CD30-expressing cells. In phase I studies, brentuximab vedotin demonstrated significant activity with...
15.
Fanale M, Forero-Torres A, Rosenblatt J, Advani R, Franklin A, Kennedy D, et al.
Clin Cancer Res
. 2011 Nov;
18(1):248-55.
PMID: 22080439
Purpose: The antibody-drug conjugate (ADC) brentuximab vedotin comprises a CD30-directed antibody covalently attached to the potent antimicrotubule agent monomethyl auristatin E (MMAE) via a protease-cleavable linker. This study explored the...
16.
Lange B, Yang R, Gan J, Hank J, Sievers E, Alonzo T, et al.
Pediatr Blood Cancer
. 2011 Jun;
57(3):398-405.
PMID: 21681921
Purpose: To assess associations of soluble IL-2 receptor alpha (sIL-2rα) concentration with outcomes in pediatric acute myeloid leukemia (AML) in a phase 3 trial of IL-2 therapy. Procedures: We randomized...
17.
Younes A, Bartlett N, Leonard J, Kennedy D, Lynch C, Sievers E, et al.
N Engl J Med
. 2010 Nov;
363(19):1812-21.
PMID: 21047225
Background: Hodgkin's lymphoma and anaplastic large-cell lymphoma are the two most common tumors expressing CD30. Previous attempts to target the CD30 antigen with monoclonal-based therapies have shown minimal activity. To...
18.
Sutherland M, Yu C, Anderson M, Zeng W, van Rooijen N, Sievers E, et al.
MAbs
. 2010 May;
2(4):440-8.
PMID: 20495353
Despite therapeutic advances, the poor prognoses for acute myeloid leukemia (AML) and intermediate and high-risk myelodysplastic syndromes (MDS) point to the need for better treatment options. AML and MDS cells...
19.
Okeley N, Miyamoto J, Zhang X, Sanderson R, Benjamin D, Sievers E, et al.
Clin Cancer Res
. 2010 Jan;
16(3):888-97.
PMID: 20086002
Purpose: SGN-35 is an antibody-drug conjugate (ADC) containing the potent antimitotic drug, monomethylauristatin E (MMAE), linked to the anti-CD30 monoclonal antibody, cAC10. As previously shown, SGN-35 treatment regresses and cures...
20.
Sutherland M, Yu C, Lewis T, Miyamoto J, Morris-Tilden C, Jonas M, et al.
MAbs
. 2010 Jan;
1(5):481-90.
PMID: 20065652
Despite therapeutic advances, the long-term survival rates for acute myeloid leukemia (AML) are estimated to be 10% or less, pointing to the need for better treatment options. AML cells express...